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Abstract
PIK3CA, the gene coding for the p110a subunit of phosphoinositide 3-kinase, is frequently mutated in a variety of human
tumors including breast cancers. To better understand the role of mutant PIK3CA in the initiation and/or progression of
breast cancer, we have generated mice with a conditional knock-in of the common activating mutation, Pik3ca
H1047R, into
one allele of the endogenous gene in the mammary gland. These mice developed a ductal anaplasia and hyperplasia by 6
weeks of age characterized by multi-layering of the epithelial lining of the mammary ducts and expansion of the luminal
progenitor (Lin
2; CD29
lo; CD24
+; CD61
+) cell population. The Pik3ca
H1047R expressing mice eventually develop mammary
tumors with 100% penetrance but with a long latency (.12 months). This is significantly longer than has been reported for
transgenic models where expression of the mutant Pik3ca is driven by an exogenous promoter. Histological analysis of the
tumors formed revealed predominantly ERa-positive fibroadenomas, carcinosarcomas and sarcomas. In vitro induction of
Pik3ca
H1047R in immortalized mammary epithelial cells also resulted in tumor formation when injected into the mammary fat
pad of immunodeficient recipient mice. This novel model, which reproduces the scenario of a heterozygous somatic
mutation occurring in the endogenous PIK3CA gene, will thus be a valuable tool for investigating the role of Pik3ca
H1047R
mutation in mammary tumorigenesis both in vivo and in vitro.
Citation: Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, et al. (2012) Physiological Levels of Pik3ca
H1047R Mutation in the Mouse Mammary Gland Results in
Ductal Hyperplasia and Formation of ERa-Positive Tumors. PLoS ONE 7(5): e36924. doi:10.1371/journal.pone.0036924
Editor: John P. Lydon, Baylor College of Medicine, United States of America
Received March 9, 2012; Accepted April 17, 2012; Published May 30, 2012
Copyright:  2012 Tikoo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia (project grant No. 628620) and the
Association of International Cancer Research (grant No 10-0052) to WAP. POH was supported by an NHMRC Career Development Award. VR was supported by the
Swiss National Science Foundation. II was supported, in part, by the Cure Cancer Australia Foundation and Cancer Australia and LH is the recipient of an Australian
Postgraduate Research Award. MS was supported by fellowships from Pfizer Australia and VESKI. The funders had no role in study design, data collectiona n d
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: MS was supported by a fellowship from Pfizer Australia. WP is a member of the PLoS ONE Editorial Board. This does not alter the authors’
adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: wayne.phillips@petermac.org
Introduction
The phosphoinositide 3-kinase (PI3K)/PTEN/AKT signaling
pathway controls a range of fundamental cellular processes which,
when de-regulated, are considered hallmarks of cancer. Members
of the class 1A PI3K form heterodimers consisting of a regulatory
subunit (p85a, p85b or p85c) and a catalytic subunit (p110a,
p110b or p110d). Among the catalytic subunits, p110a, encoded
by the PIK3CA gene has been shown to be mutated and activated
in many human cancers [1,2,3]. Approximately 80% of the
mutations identified in this gene are concentrated in three ‘hot
spot’ positions, two of which are in exon 9 (E542K and E545K)
and one in exon 20 (H1047R).
PIK3CA mutations have been observed in up to 40% of breast
cancers including both ductal and lobular histological subtypes [1,4].
PIK3CA mutations have also been detected in ductal carcinoma in
situ(DCIS), a precursorofbreast cancer[5,6,7],suggesting theymay
play a role in tumor initiation rather than progression [7].
The direct impact of PIK3CA mutations on clinical outcome
remains unclear. While PIK3CA mutations have been associated
with poor survival [8,9,10], others have reported an association
with improved outcome [11]. Similarly, while frequently found in
estrogen receptor (ER) positive and HER2 positive tumors [12,13],
which tend to have a more favorable prognosis [14,15], PIK3CA
mutations also appear to reduce the efficacy of HER2-targeted
treatments [16,17,18].
In vitro studies have demonstrated that the expression of PIK3CA
mutations in cell lines increase AKT activation and result in
morphological changes, increased proliferation and anchorage-
independent growth, consistent with an oncogenic role [19,20,21].
Moreover, recent mouse models have reported tumor formation
following expression of Pik3ca mutations in mammary cells
[22,23,24]. Importantly, these models have used a transgenic
approach, where the expression of the mutant protein is under the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36924control of an exogenous promoter potentially leading to its over-
expression. Over-expression of wild-type PIK3CA has also been
shown to be oncogenic [25,26] and studies on the K-ras oncogene
have demonstrated that endogenous expression of the K-ras
G12D
mutation has very different biological effects compared to
transgenic over expression [27].
We have previously generated a novel mouse model with a
conditional, Cre recombinase (Cre)-inducible ‘knock-in’ of the
Pik3ca
H1047R mutation [28]. Here, we have generated mice with
the H1047R mutation knocked into one allele of the endogenous
Pik3ca gene of the mammary epithelial cell compartment. In this
model, expression of the mutant protein is driven by the
endogenous promoter and thus is expressed at physiological levels
and only in cells that normally express Pik3ca. This model
accurately reproduces the scenario of a somatic mutation in a
single PIK3CA allele as occurs in human breast tumors making it
ideal for both studying the role of PIK3CA mutation in
tumourigenesis and for preclinical studies evaluating therapies
targeting the PI3K pathway.
Materials and Methods
Experimental animals
Mice with targeted expression of a H1047R mutation to one
allele of the Pik3ca gene of epithelial cells in the mammary gland
were generated by crossing a female mouse harboring a latent,
Cre-inducible knock-in of the Pik3ca
H1047R mutation (C57BL/6-
Pik3ca
Lat-H1047R) [28] with a transgenic male mouse (FVB/N-Tg -
MMTV-Cre) expressing Cre under the control of the murine
mammary tumor virus (MMTV) promoter [29,30] obtained from
Jane Visvader (WEHI, Melbourne, Australia). Littermates (includ-
ing wild type, Pik3ca
Lat-H1047R alone, and MMTV-Cre alone) were
used as controls. C57BL/6-(ROSA)26Sor mice, which carry a
ubiquitously expressed LacZ transgene, in otherwise wild-type
mice, were crossed with (FVB/N-Tg-MMTV-Cre) and used for
verification of Cre-recombination, by staining for LacZ (b-
galactosidase) activity in the harvested mammary gland [31].
Severe combined immunodeficiency (SCID) mice were purchased
from the Animal Resource Centre, Canning Vale, Australia.
All experimental procedures involving animals were approved
by the Peter MacCallum Cancer Centre Animal Experimental
Ethics Committee (AEEC No. E406) and conducted in accor-
dance with the NHMRC Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes. All mice were maintained and
housed in the animal facility of the Peter MacCallum Cancer
Centre. All mice were closely monitored and immediately
humanely euthanized when the tumors reached a total volume
of 1.3 cm
3 or at any sign of discomfort and/or stress (whichever
came first).
Whole mount/Ductal measurements
Whole inguinal mammary glands from 10 mice of each
genotype were dissected out, mounted and spread onto superfrost
glass slides, fixed overnight in Carnoy’s fixative (ethanol,
chloroform, glacial acetic acid 6:3:1) followed by rehydration
and overnight staining with carmine red stain [1 g carmine red
dye (Sigma), 2.5 g potassium alum in 500 ml water]. The mounts
were dehydrated, cleared in xylene and mounted in Entellan
(HX930910, Merck). The slides were scanned using 46objectives
(IX81, Olympus). The number and size of terminal end buds
(TEB) were measured using Meta Imaging series 7.1 (Metamorph,
Molecular Devices Corporation). The measured values 6
standard deviation was plotted using GraphPad Prism and
statistical significance was calculated using Student’s t-test.
Histology and Immunohistochemistry
Formalin-fixed and paraffin-embedded (FFPE) tissue sections
were stained with Hematoxylin and eosin (H&E) for histopatho-
logical analysis. For immunohistochemistry (IHC) and immuno-
fluorescence (IF) analysis, standard protocols (http:/www.
cellsignal.com/support/protocols) were followed. Briefly, antigen
retrieval with Tris-EDTA (pH 8) was used for anti-PCNA, keratin
5 (K5), E-cadherin, keratin 8 (K8) and pAKT antibody staining
while sodium citrate buffer (pH 6.0) was used for anti-ERa, and
pS6 antibodies. Sections (4 mm) were incubated with 3% H2O2 to
inactivate endogenous peroxidase, and blocked with 3% (v/v) pre-
immune goat serum (DakoCytomation) in PBS-T (PBS containing
0.05% Tween-20) for 30 min at room temperature. Primary
antibodies were applied overnight at 4uC or for 1 hour at room
temperature, followed by 1 hour incubation with appropriate
secondary antibodies containing different labels as required by
IHC and IF procedures. Negative control slides were run with
non-immune serum, where possible, or without primary antibody
prior to incubation with their corresponding secondary antibody.
For IF, the primary antibodies included K8 (ab104053, Abcam),
K5 (PRB16-P, Covance) and E-cadherin (6-10182, BD Bioscienc-
es-Pharmingen). While Alexa FluorH anti-rabbit (A11008, Invitro-
gen), anti-chicken (A11041, Invitrogen) and anti-mouse antibodies
(A31571, Invitrogen) were used as secondary antibodies. Slides
were mounted in ProlongH Gold stain with DAPI (P36935,
Invitrogen) before imaging using appropriate excitation filters on
an Olympus BX-51 fluorescence microscope.
For IHC, the primary antibodies included K8/18 (GP-11,
Upstate), p63 (sc-8431, Santa Cruz Biotechnology, Inc.), ER (sc-
542, Santa Cruz Biotechnology, Inc.), pAKT S473, (3787, Cell
Signaling Technology), pS6 (2211, Cell Signaling Technology),
PCNA (6-106-6-5, BD Biosciences). IHC slides were incubated
with HRP-labeled anti-mouse or goat anti-rabbit secondary
antibodies (DakoCytomation) and visualized using an Envision
+Dual link system kit (DakoCytomation). The slides were imaged
using 620 objective and digitally scanned using Aperio digital
pathology system (Scan ScopeHXT). Nuclear stain scoring such as
in the case of anti-PCNA staining was performed using Image
Scope software provided with the Aperio scanner.
b-galactosidase staining
Mammary tissues and mammary whole mounts from (RO-
SA)26Sor:MMTV-Cre and (ROSA)26Sor control mice were fixed
with 2% paraformaldehyde/0.2% glutaraldehyde solution fol-
lowed by 20% sucrose solution. For histology, tissue was frozen in
OCT mounting medium and stored at 280u and 10 mm sections
used for staining. Cre-mediated recombination, where present,
was identified using X-Gal (V3941, Promega Corp.) and
counterstained with nuclear fast red using 10 mm sections [28].
Mammary epithelial cell preparation
Mammary epithelial cells were isolated from the mammary
glands of 6 week old female mice cell using a method previously
described [32]. Briefly, after mechanical dissociation of the
dissected mammary glands using a scalpel blade, the mammary
tissue was placed in culture medium containing 300 U ml
21
collagenase (Roche Diagnostics). The resultant organoid suspen-
sion was sequentially resuspended in 0.25% trypsin-EDTA for
2 min followed by incubated in buffer containing 5 mg ml
21
dispase (Roche Diagnostics) and 0.1 mg ml
21 DNase (Worthing-
ton) for 5 min. After incubation, the cell pellet was resuspended in
NH4Cl (0.8%) for 3 min to lyse contaminating red blood cell, then
washed with PBS and filtered through a 40-mm mesh. The
resulting epithelial cells were either used for labeling and flow
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1 mM glutamine, 5 mgm l
21 insulin, 500 ng ml
21 hydrocortisone,
10 ng ml
21 epidermal growth factor) supplemented with 5% fetal
bovine serum (FBS), for immortalization and generation of cell
lines.
Cell labeling and flow cytometry
Freshly isolated mammary epithelial cells were incubated at 4uC
for 30 minutes with appropriate antibodies including PE-CD24
(55326-2, BD Biosciences-Pharmingen), FITC-CD29 (555005BD
Biosciences), PECy7-CD31 (56-1410 BD-Pharmingen), PECy7-
CD45.1 (56-0578 BD-Pharmingen), bio-CD61 (557853 BD-
Pharmingen), PECy7-TER119 (553345 BD-Pharmingen), and
APC-Streptavidin (17-4317-82, e-Bioscience. Inc.). After antibody
labeling, the cells were washed and resuspended in FACS buffer
(PBS+2% FBS) containing viability stain 0.5 mgm l
21 propidium
iodide, or 10 ng/ml DAPI). The labeled viable single cells were
analyzed and sorted using a Fluorescence-activated cell sorter
(FACS). Non-epithelial cell populations were excluded from
freshly isolated mammary cell suspensions by gating on the cells
using well characterized PECy7-conjugated endothelial (CD31)
and hematopoietic (CD45 and TER119) antigens. As previously
detailed [32], the remaining live CD45
2CD31
2TER119
2 (Lin
2)
cells were sorted based on FITC-CD29, PE-CD24 and APC-
CD61 labeled cells and collected using FACSDiVa or FACSAr-
ia
TMII (Becton Dickinson). Consequently, the Lin
2CD29
hiCD24
+
cells represent the basal cell population (enriched for stem cells,
which possess multi-lineage differentiation capacity) while Lin
2C-
D29
loCD24
+ cells represent the luminal population. The luminal
population was further sorted on the basis of CD61 expression
where Lin
2CD29
loCD24
+CD61
+ cells represent the luminal
progenitor cell population [33]. After sorting the cells were
routinely re-analyzed to confirm purity and viability were greater
than 95%.
2D proliferation assay for FACS sorted cells
For colony assays, FACS sorted cells were plated into duplicate
wells of 12-well plates containing a feeder layer of irradiated NIH-
3T3 cells. Cells were allowed to form colonies in growth medium
containing 20 ng ml
21 of cholera toxin for 7 days before staining
with 0.05% crystal violet. Numbers of colonies were counted and
plotted using GraphPad Prism.
Generation of immortalized mammary epithelial cell lines
Mammary epithelial cells from 6 week old mice were isolated
and immortalized using dominant-negative p53 and E1A as
previously described [34]. In the first instance, we isolated and
immortalized mammary epithelial cells from mice heterozygous
for the latent mutant allele (Pik3ca
Lat-H1047R) and induced the
mutation by infection with a retrovirus expressing a pMSCV-Cre-
IRES-GFP construct (a kind gift of Kay Macleod, University of
Chicago, USA) [35] while MSCV-IRES-GFP infected cells were
used as controls. Transduced cells were enriched by using FACS to
select for GFP positive cells.
We also prepared mammary epithelial cells from mice already
expressing the Pik3ca
H1047R mutation (Pik3ca
H1047R: MMTV-Cre
mice) and wild type controls (MMTV-Cre only mice). These cells
were either used immediately as primary cells or immortalized
with dominant-negative p53/E1A as described above.
All cell lines were maintained in (DMEM-F12 containing 1 mM
glutamine, 5 mgm l
21 insulin, 500 ng ml
21 hydrocortisone,
10 ng ml
21 epidermal growth factor) supplemented with 5%
FBS, and cultured at 37uCi n5 %C O 2. Knock-in of the mutation
was confirmed in all cell lines by cDNA sequencing.
In vitro experiments using iMMECS
The proliferative potential of mutant cells compared to control
cells was assessed by direct cell count using a coulter counter or by
confluence measurements using an IncuCyte
TM live cell imaging
system. For analysis of tumor forming potential, 3610
6 freshly
isolated primary mammary epithelial primary cells, or immortal-
ized cell lines, in 30 ml of a mixture of PBS and 50% Matrigel (1:1),
were injected into the inguinal mammary fat pad of 4–6 week old
SCID mice. Tumor growth was monitored using calipers and the
mice sacrificed and tumors harvested when the tumor burden
reached .1.4 cm
3 or at signs of severe illness (hunching, ruffled
fur or distress).
Statistics
All statistical analyses were performed using GraphPad Prism 5
software. Statistical analyses were performed using a 2-tailed
Student’s t-test or Log-rank (Mantel-Cox) Kaplan-Meier survival
test, as appropriate. p values,0.05 were considered statistically
significant.
Results
Expression of Pik3ca
H1047R in the mouse mammary gland
To examine the role of Pik3ca
H1047R mutation during mammary
development and its ability to induce mammary tumors, we
targeted the mutation to the mammary gland. Mice harboring a
latent Cre-inducible Pik3ca
Lat-H1047R allele [28] were crossed with
mice expressing Cre under the control of the MMTV promoter
[29] resulting in mice heterozygous for Pik3ca
H1047R expression in
the mammary gland (Figure 1A). Successful knock-in and
mutation expression was confirmed by sequencing of RNA
isolated from the mammary gland of mutant mice (Figure 1B,
C). No mutation was detected in RNA isolated from wild-type
mice (Figure 1B, C). Similarly no mutation was detected in
MMTV-Cre alone or Pik3ca
Lat-H1047R alone control mice (data not
shown). Mammary epithelial cell expression of Cre driven by
MMTV was confirmed by crossing MMTV-Cre mice with a
transgenic mouse bearing a Cre-inducible LacZ allele at the
(ROSA)26Sor locus (Figure 1D).
Pik3ca
H1047R expression in the developing mammary
gland results in enhanced ductal morphogenesis
We examined the effect of Pik3ca
H1047R expression on the
mammary gland at various developmental stages including
puberty (6 weeks of age) and early adulthood (12 weeks) and
during pregnancy (day 14) and involution (5 days post weaning).
Mutant female mice could produce milk and suckle the pups as
normal. Also, the pups of the Pik3ca
H1047R mutant mothers were
healthy and gained weight similar to the pups from the control
mothers, suggesting that expression of the Pik3ca
H1047R mutation
did not adversely effect lactation. At the macroscopic level,
Pik3ca
H1047R expressing mammary glands appeared to develop
normally. However, microscopic examination of mammary gland
whole mounts showed that Pik3ca
H1047R expression altered ductal
morphogenesis, as evidenced by increased number and size of
invading terminal end buds (TEB) at 6 weeks (Figure 2A, Ci and
Cii), and increased secondary and tertiary branching at 12 weeks
of age (Figure 2B). Furthermore, the ducts of the Pik3ca
H1047R
expressing mammary glands at both 6 and 12 weeks were
noticeably dilated (Figure 2A, 2B) with significantly larger cross
sectional diameter (Figure 2Ciii, Civ respectively). Interestingly,
during pregnancy (day14) or involution (day5) the mammary
glands of Pik3ca
H1047R mutant mice showed no noticeable
difference compared to control mice (data not shown).
Pik3ca
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mice showed that, while most ducts in the mammary glands of
control mice had a clear lumen, the lumen of the ducts in
Pik3ca
H1047R mutant mammary glands were filled with cells
(Figure 3A). Similarly, the majority of ducts in 12 week old
mutant mice were enlarged compared to wild type controls and
displayed areas of multilayered epithelium, which was hyperplastic
in some regions, and showed presence of an eosinophilic luminal
secretion (Figure 3B). In addition, the mutant ducts were
surrounded by an increase in number of stromal cells, as evident
by eosin staining, a phenotype that was not observed in the ducts
of control mice. The increased periductal stroma stained positively
for a-smooth muscle actin (Supplementary Figure S1A) but
showed no reactivity to the epithelial cell markers p63, K5 or
K8 (data not shown). Interestingly, enhanced PI3K pathway
activity, as assessed by immunohistochemistry for pAKT or pS6,
was not evident at these early developmental time points (6 and 12
weeks).
Co-immunofluorescence using anti-K5, anti-K8 and anti-E-
cadherin antibodies, together with DAPI to stain the nuclei, was
used to study the ductal epithelium of the Pik3ca
H1047R mice. In the
normal mammary gland from 6 week old mice K5 stained the
Figure 1. Pik3ca
H1047R inducible knock-in mouse model. (A) A schema outlining the generation of mice expressing Pik3ca
H1047R in the
mammary gland. Mice heterozygous for the latent mutant allele (Pik3ca
wt/LatH1047R) were crossed with mice heterozygous for the transgenic MMTV–
Cre allele (MMTV-Cre
2/+). Cre-mediated recombination results in the excision of everything between the LoxP sites (triangles) allowing the mutant
version of exon 20 (dark rectangle) to replace the wild type exon 20, thus generating mice that express the Pik3ca
H1047R mutation in mammary
epithelial cells. (B) Cre-mediated knock-in of the mutant exon 20 was confirmed by sequencing RNA extracted from the mammary fat pad (MFP) from
heterozygous Pik3ca
H1047R:MMTV-Cre (HET) and Pik3ca
wt (WT) mice. RNA extracted from WT and HET MFP was reverse transcribed into cDNA and
sequenced from exon 19 into exon 20 (exon 19-specific primer: 59-CAAGAGTACACCAAGACCAGAGAGTT-39) and confirmed by sequencing in the
reverse direction from exon 20 (59- TCCAATCCATTTTTGTCGTCC-39). Shown are the expected sequences (1, 2) and the actual sequence traces (3, 4) for
cDNA from WT MFP (Pik3ca control) (1, 3) and HET-MFP (Pik3ca mutant) (2, 4). Note that the representative cDNA sequence from the HET-MFP is
heterozygous at the sites of silent base changes engineered into the mutant exon 20 [28] confirming successful knock-in of the Pik3ca
H1047R mutation
in HET MFP. (C) The section of the sequencing trace from (B) showing the region spanning position 1047 showing the bases changes responsible for
the HisRArg substitution (*). (D) Whole mounts (i) and 10 mm sections (ii) of mammary tissue from (ROSA)26Sor control mice (left) and
(ROSA)26Sor:MMTV-Cre mice (right) were stained using X-Gal and counterstained with nuclear fast red. MMTV-Cre-mediated recombination, where
present, is identified by blue staining. Scale bar, 50 mm.
doi:10.1371/journal.pone.0036924.g001
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the Pik3ca
H1047R mutant mammary gland, in addition to staining
the outer epithelial cell layer of TEB and ducts, K5 positive cells
were also present in the body of the TEB and in luminal epithelial
layers of the ducts (Figure 3C, thick arrows), suggesting anaplasia
of basal cells in the mutant mammary gland. Anaplasia of basal
cells was confirmed by anti-p63 immunohistochemistry (arrow,
Supplementary Figure S1B). As expected, K8 positive cells lined
the lumen of both the control and the mutant mice (Figure 3C). In
particular, the multilayered epithelium of the Pik3ca
H1047R mutant
ducts was K8 positive (Figure 3C). Immunohistochemistry
confirmed the majority of multilayered epithelium stained
positively for anti-K8/18 antibody (Supplementary Figure S1C).
E-cadherin immunostaining showed that K8 positive cells mostly
co-stained for E-Cadherin. While E-cadherin was present in the
lateral walls in most of the cells of the mammary ducts from
mutant mice, although some ducts also showed diffused and/or
reduced lateral cell wall staining, suggestive of some loss of polarity
as early as six weeks (Figure 3C). Loss of polarity in the epithelium
was confirmed at 6 weeks by anti-b-Catenin immunostaining
showing reduced membrane staining and increased nuclear
staining in many of the ducts from Pik3ca
H1047R mutant mice
(Supplementary Figure S1D). Similar results were observed in
mammary glands from 12 week old mice (Figure 3D).
Pik3ca
H1047R expression results in expansion of the
luminal progenitor population
The increased cell number observed within the epithelium of
the ducts and TEB expressing Pik3ca
H1047R did not appear to be
due to reduced apoptosis as there was no significant difference in
TUNEL staining when compared to control mammary glands
(data not shown). However, increased proliferation within the
multilayered epithelia of the Pik3ca
H1047R expressing ducts and
TEB was detected by anti-PCNA staining (Figures 4A, 4B).
In order to explore the origin of cells in the multilayered
epithelium, we used FACS analysis to isolate the various
subpopulations of the mammary epithelial cells. Epithelial cells
from control and Pik3ca
H1047R expressing mammary glands from 6
week old mice were isolated and sorted using anti-CD29 and anti-
CD24. While the FACS profiles for the Pik3ca
H1047R expressing
and wild type cells were similar (insert on Figure 4C), the
Lin
2CD29
loCD24
+ (luminal cell) population was increased in the
Pik3ca
H1047R expressing mice as compared to control mice
(Figure 4C). Furthermore anti-CD61 antibody was used to
separate the luminal cells into mature and progenitor populations.
A significant increase in the number of Lin
2CD29
loCD24
+CD61
+
(luminal progenitors) was observed in the Pik3ca
H1047R expressing
mice (Figure 4D). We also found that when allowed to form
colonies on an irradiated feeder layer of cells, colony forming
ability of either Lin
2CD29
hiCD24
+ (the stem cell enriched basal
population) or Lin
2CD29
loCD24
+CD61
+ (luminal progenitors)
was significantly enhanced in the cells from Pik3ca
H1047R mutant
Figure 2. Expression of Pik3ca
H1047R in developing mammary gland increases ductal morphogenesis. Mammary gland whole mounts
from mice at 6 weeks (A) or 12 weeks (B) of age were stained with carmine red and visualized by scanning microscopy. Shown are representative
whole mounts from mutant expressing Pik3ca
H1047R:MMTV-Cre (Pik3ca mutant) mice as well as from wild type, Pik3ca
Lat/H1047R alone and MMTV-Cre
alone, control mice. N, nipple. L, lymph node. Scale bar, 500 mm. Insets show higher magnification of boxed region (scale bar of insets, 50 mm). (C)
Morphometric analysis using MetaMorph software was used to quantify (i) the number of terminal end buds (TEB) in the mammary gland of 6 week
old mice (n=10), (ii) the area of the ten largest TEB in 6 week old mice (n=10 mice). The diameter of 20 randomly selected ducts (n=5 mice), was
measured at a point equi-distant from the nipple, in control and mutant-expressing mammary glands from 6 week old (iii) and 12 week old (iv) mice.
Shown are mean 6 SD. Lat, Pik3ca
LatH1047R alone; Wt, wild type; Cre, MMTV-Cre alone; and Mut, Pik3ca
H1047R: MMTV-Cre. ** denotes p,0.005; ***
denotes p,0.0001 (two tailed t-test) between Pik3ca mutant and any of the control group.
doi:10.1371/journal.pone.0036924.g002
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addition the size of the colonies formed by either cell population
from mutant mice was larger than the colonies from wild type
mice (inserts in Figure 4E, F). Neither the mature luminal cells nor
the remaining (rest) cell populations from either the mutant or
control mammary glands formed any colonies in similar assay.
Figure 3. Expression of Pik3ca
H1047R in developing mammary gland induces ductal hyperplasia. (A, B) Formalin-fixed paraffin-embedded
sections of mammary glands from control and mutant (Pik3ca
H1047R–expressing) mice were stained with hematoxylin and eosin (H&E). Shown are
representative sections showing the presence of a multilayered epithelium (arrow) in the ducts of Pik3ca
H1047R –expressing mammary gland from 6
week old mice (A) and regions of hyperplastic epithelium (arrow) in the Pik3ca
H1047R expressing mammary gland of 12 week old mice (B). Sections
from control and mutant mammary glands are pictured at same magnification (scale bar 50 mm). (C, D) Representative sections were also stained for
K5 (green), K8 (red) and E-cadherin (pink) using immunofluorescence. DAPI (blue) was used to stain nuclei. Note that, in addition to staining the basal
layer of the epithelium, K5 also stains anaplastic cells (arrows) in the terminal end buds (TEB) and ducts of the Pik3ca
H1047R –expressing mammary
gland of 6 week (C) or 12 week mice (D). All sections were imaged at the same magnification using appropriate excitation filters. Scale bar, 50 mm.
doi:10.1371/journal.pone.0036924.g003
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H1047R increases cell proliferation and enrichment of luminal progenitors in vivo. (A) Representative sections of control
and mutant (Pik3ca
H1047R-expressing) mammary glands from 6 week old mice stained with anti-PCNA antibody. Scale bar, 100 mm. Insets show lower
magnification image of surrounding region. (B) The percentage of PCNA positive cells in ducts and terminal end buds (TEB) of control and mutant
mammary glands. Shown are mean 6 SEM from 3 mice (7 TEB and 7 ducts per mouse). * indicates p,0.05 and ** indicates p,0.005 compared to
respective controls (two tailed t-test). (C) Freshly isolated Lin
2ve epithelial cells from the mammary glands of 6 week old mice were sorted on the
basis of CD24 and CD29 expression (insets) and the percentage of cells in the Basal (b, Lin
2veCD29
hiCD24
+), Luminal (l, Lin
2veCD29
loCD24
+) and the
‘Rest’ (r) populations calculated. Shown are mean 6 SEM for Pik3ca
H1047R mutant (n=5) and Pik3ca
Wt control (n=9). (D) The luminal cell population
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H1047R expression leads to mammary gland
hyperplasia and tumorigenesis
Cohorts of Pik3ca
H1047R expressing and wild type female
(nulliparous and biparous) mice were set aside for ageing and
followed for tumor development. Examination of mammary whole
mounts from 13 month old nulliparous (Figure 5Ai) and biparous
(Figure 5Aii) mice revealed enlarged ducts, particularly in the
nipple region of the biparous mice (Figure 5Aii), and small focal
lesions in the mutant glands (arrowed in Figures 5Ai; Aii).
Histological examination revealed the mammary glands of aged
mutant mice had ectatic ducts filled with eosinophilic luminal
secretions (Figure 5B). However, unlike at earlier time points, the
activation of PI3K pathway in the ductal cells of aged mutant mice
was detectable using pAKT (data not shown) or pS6 staining
(Figure 5B). Two microscopic foci of sclerosis adenosis and one
small intraductal fibroadenoma were noted in the Pik3ca
H1047R
expressing glands (Figure 5C). Activation of the PI3K pathway was
evident in the area of sclerosis adenosis as indicated by increased
expression of pAKT (not shown) and also pS6 (Figure 5C). These
foci were also ERa positive (Figure 5C).
Ageing mice beyond 12 month resulted in tumor formation in
the mutant mice cohort. As shown in Figure 5D, all nulliparous
and biparous Pik3ca
H1047R expressing female mice were culled due
to the development of mammary tumors. While the nulliparous
cohort had a median tumor-free survival of 484 days, the tumor
formation was significantly accelerated in biparous mutant mice
with a median tumor-free survival of 393 days. All mice were
otherwise disease free and all other tissues showed normal
histology in both mutant and control mice. No macroscopic
metastasis was found under these experimental conditions;
however it should be noted that the mice were culled when the
primary tumors reached a predetermined, ethically-limiting, size.
Sequencing analysis of RNA confirmed the presence of the
Pik3ca
H1047R mutation in all tumors.
Histopathological assessment of the tumors revealed that they
were a mix of benign fibroadenomas (45%), carcinosarcomas or
sarcomas (42.5%), adenoquamous carcinomas (10%) and an
osteosarcoma (2.5%) (Figure 6Ai–iii). Due to the frequent
occurrence of biphasic tumors with both epithelial and mesen-
chymal elements (fibroadenomas and carcinosarcomas), we
investigate the potential role of bipotent progenitor cells in tumor
formation and the effect of Pik3ca mutation on epithelial–
mesenchymal transition (EMT). Immunofluorescence and immu-
nohistochemical analysis of tumor sections revealed the presence
of basal-like (K5/6 positive) and luminal-like (K8/18 positive)
epithelial cells in fibroadenomas (Figure 6Ai) and carcinosarcomas
(Figure 6Aii) while the squamous elements of the adenosquamous
carcinomas (Figure 6Aiii) contained only K5/6 positive cells.
Notably, some fibroadenomas and carcinosarcomas contained
cells that showed co-localization of K5 and K8 staining.
Furthermore, while some of the ductal structures and K8 positive
cells retained E-cadherin expression in lateral junctions, presum-
ably due to normal ducts trapped in the tumor mass, most K8
positive cells showed diffuse or reduced E-cadherin staining. On
the other hand, the adenosquamous carcinomas stained positively
for K5 but did not express K8 and E-cadherin (Figure 6B, iii).
Activation of PI3K pathway in tumors was confirmed by
immunostaining for pAKT (Figure 6A) and pS6 (data not shown)
and western blotting for pAKT and pS6 (Figure 5E). GSK3b was
also phosphorylated in these tumors, as well as in non-tumor
mammary gland tissue from the Pik3ca
H1047R mutant mice
(Figure 5E).
Cells from Pik3ca
H1047R-induced tumors maintain
malignant potential
To examine whether cells from Pik3ca
H1047R-induced tumors
could maintain their malignant potential, pieces of the Pik3-
ca
H1047R tumors were disaggregated and allowed to grow in 2D
culture, resulting in the generation of cell lines without need for
immortalization. When injected into the mammary fat pad of
SCID mice these cell lines (MH232 and MH248) formed tumors
within 14 days (Table 1 and Figure 7Ci).
In vitro knock-in of the Pik3ca
H1047R mutation induces
transformation of immortalized mammary epithelial cells
To test the tumorigenic potential of the Pik3ca
H1047R mutation
in vitro, we prepared immortalized mammary epithelial cells from
mice heterozygous for the latent mutant allele (Pik3ca
Lat-H1047R)
and induced the knock-in of the mutation by infection with a Cre-
expressing retrovirus (pMSCV-Cre-IRES-GFP). The resulting
Pik3ca
H1047R expressing cells (HB158
+) grew faster than cells
infected with the control retrovirus pMSCV-IRES-GFP (HB158
2)
(Figure 7A) and exhibited constitutive activation of the PI3K
pathway as evidenced by increased pAKT, pGSK3b and pS6
levels, both with and without serum stimulation (Figure 7B). The
Pik3ca
H1047R expressing cells (but not the un-induced controls)
were also tumorigenic forming tumors when injected into the
mammary fat pads of immunocompromised mice (Table 1 and
Figure 7Ci). Analysis of tumor sections showed undifferentiated
carcinomas that had an activated PI3K pathway, as shown by pS6
positivity (7Ciii), and were ERa-positive (Figure 7Civ).
We also examined the tumor-forming capacity of immortalized
Pik3ca
H1047R expressing mammary cells prepared from Pik3-
ca
H1047R: MMTV Cre mice. Similar to HB158
+, the Pik3-
ca
H1047R-expressing cell lines (MH72 and MH102) grew quicker
than the non-expressing control cells (MH140) in 2D culture (data
not shown) and formed tumors when injected into immunocom-
promised mice (Table 1). No tumors were formed from the control
cells. Interestingly, primary (non-immortalised) Pik3ca
H1047R ex-
pressing cells failed to produce tumors in immunocompromised
mice (Table 1 and Figure 7Ci) suggesting that Pik3ca
H1047R
expression alone is insufficient to induce transformation of
mammary epithelial cells in vitro.
Discussion
Mutations in the PIK3CA gene are found in up to 40% of
human breast cancers [1,4] and in vitro expression of these
mutations in cell lines has suggested that they are oncogenic
[20,36]. Here we have generated mice with a conditional knock-in
of the Pik3ca
H1047R mutation targeted to the mammary gland, in
order to investigate the role of this mutation in mammary
tumorigenesis in vivo.
was further sorted on basis of CD61 to generate a luminal progenitor (LP, Lin
2veCD29
loCD24
+ CD61
+) and non-progenitor (LM) populations. Shown
are mean 6 SEM for Pik3ca
H1047R mutant (n=5) and Pik3ca
Wt control (n=9). (E&F) The various cell populations (1610
3 cells) were plated on a layer of
irradiated NIH3T3 cells and after 9 days stained with 0.05% crystal violet. The number colonies formed by Lin
2veCD29
hiCD24
+(Basal) (E) and
Lin
2veCD29
loCD24
+ CD61
+ (luminal progenitor) (F) populations were counted. Shown are mean 6 SEM for Pik3ca
H1047R mutant (n=5) and Pik3ca
Wt
control (n=9). ** indicates p,0.005 and *** indicates p,0.001 compared to respective controls (two tailed t-test).
doi:10.1371/journal.pone.0036924.g004
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transgenic approach, where expression of the mutant allele driven
by an exogenous promoter [22,23,24] we have inserted the
mutation into the endogenous Pik3ca gene so that expression of the
mutant allele is under the control of the endogenous promoter. As
a result, the mutation is expressed at physiological levels and only
in cells that would normally express Pik3ca thus mimicking the
scenario of a heterozygous somatic mutation in the endogenous
gene, as occurs in human tumors.
We found that expression of Pik3ca
H1047R in the epithelial cells
of the mammary gland results in an epithelial hyperplasia
detectable by 6 weeks of age. Such early changes suggest that
the Pik3ca mutation may be an early event in breast cancer
development, a result consistent with findings of PIK3CA
mutations in DCIS [5,6,7]. Increased proliferative capability of
mammary epithelial cells, as a consequence of Pik3ca mutation,
potentially makes the cells susceptible to further mutations.
Increasing evidence shows that early genetic alterations in mouse
mammary gland progenitor or luminal cells, which result in
changes such as hyper-proliferation, are involved in tumor
initiation [37,38,39,40,41].
We found increased ductal morphogenesis in the Pik3ca
H1047R-
expressing mammary glands of pubertal and young adult mice.
This is consistent with results showing that activation of the PI3K/
AKT pathway, by activation of receptor tyrosine kinases or loss of
PTEN, has been linked to increased mammary duct growth and
branching [42,43,44,45]. Also, inhibition of PI3K activity has
been shown to block both ductal elongation and branching [46,47]
suggesting a role for the PI3K/AKT pathway in this process.
However, expression of a constitutively activated Akt in the mouse
mammary gland shows no major changes in ductal morphogenesis
[48,49], suggesting the possibility that the ductal morphogenesis
observed in the developing Pik3ca mutant mammary glands might
be controlled by AKT independent pathways [49].
Pik3ca
H1047R expressing mice eventually formed mammary
tumors but only after a long latency of 12–18 months. The
development of tumors was significantly accelerated by pregnancy
but the mean survival for biparous mice was still more than 12
months. In human cancer, PIK3CA mutations are detected in
Figure 5. Expression of Pik3ca
H1047R induces pre-neoplastic lesions and tumorigenesis in aged mice. (A). Representative whole mounts
of control (MMTV-Cre alone) and mutant (Pik3ca
H1047R:MMTV-Cre) mammary glands from 13 month old nulliparous (i) and biparous (ii) mice. Arrows
indicate foci of sclerosis adenosis. Scale bars, 500 mm. (B) Representative sections from control (MMTV-Cre alone) and mutant (Pik3ca
H1047R:MMTV-
Cre) mammary glands from 13 month old biparous mice were stained with H&E or anti-pS6 antibody. Scale bars, 100 mm. (C) Representative
sclerosing adenosis lesion from Pik3ca
H1047R-expressing mammary glands from aged (.12-month) old mice were stained with H&E, and with anti-pS6
and anti-ERa antibodies. Scale bars, 100 mm. (D) Kaplan-Meier survival curves for aged control and mutant (Pik3ca
H1047R:MMTV-Cre) mice. Shown are
nulliparous (green broken line, n=10) and biparous (blue solid line, n=11) and respective control mice (nulliparous, gray line, n=30; biparous,
orange line, n=10). ** The median tumor free survival in biparous mice was significantly (p,0.005) reduced compared to nulliparous mice. (E) Protein
lysates from control and mutant mammary glands and tumor tissue from nulliparous aged (.12 month) mice were separated by SDS-PAGE and
immunoblotted for analysis of PI3K pathway activation using anti-pAKT, anti-pGSK3b, and anti-pS6, as well as anti-tubulin (loading control).
Immunoreactive proteins were detected with horse-radish peroxidase conjugated secondary antibodies and visualized with enhanced
chemiluminescence. Samples are identified by their corresponding mouse ID. MG, mammary gland.
doi:10.1371/journal.pone.0036924.g005
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the tumorigenic process and that, presumably, other mutational
events are required to initiate progression to invasive carcinoma.
Similarly, hyperplastic changes induced by Pik3ca
H1047R expression
alone, as early as 6 weeks of age, are consistent with the earliest
events in the tumorigenic process. The long latency for tumor
formation may therefore suggest a secondary event is required for
progression to cancer.
Interestingly, we could not detect enhanced activity of the
PI3K/AKT pathway in the Pik3ca
H1047R-expressing mammary
gland of 6 and 12 week old mice but increased pAKT and pS6
were clearly evident in the mutant ducts of adult mice. It is possible
that, at early stages of development phosphatases, such as PTEN,
or negative feed-back mechanisms may counteract increased
signaling induced by mutant Pik3ca but that, over time,
accumulation of other mutations eventually leads to a reduction
in these regulatory mechanisms with subsequent expression of
constitutive PI3K/AKT activity and, ultimately, tumorigenesis.
Consistent with this hypothesis, we have recently shown that
Pik3ca
H1047R expression in the mouse ovary does not, by itself,
induce cancer but can synergise with Pten loss to rapidly induced
tumorigenesis [28].
The time required for tumor development observed in our
model is significantly longer than that reported for the transgenic
Pik3ca
H1047R models [22,23,24]. The reasons for this are not clear
but it is possible that the exogenous promoters used in the
transgenic models may result in higher levels of expression of the
mutant protein resulting in the endogenous regulatory mecha-
nisms being overcome.
In contrast to our in vivo model where only ductal hyperplasia is
observed at 6 weeks, the in vitro induction of the Pik3ca
H1047R
mutation in immortalized mammary epithelial cells from 6 week
old mice resulted in a strong tumorigenic phenotype when injected
into the mammary fat pad of immuno-deficient recipient mice. It
is noteworthy that tumor formation was not observed in primary
cells from either Pik3ca
H1047R mutant or control mammary
epithelial cells but only in Pik3ca
H1047R mutant cells that had been
immortalized by expression of dominant negative p53 and E1A. A
cooperative interaction between Pik3ca
H1047R and p53 loss-of-
function has previously been reported in an in vivo mouse model of
mammary cancer [22]. This raises the possibility that the
tumorigenic activity we observed following expression of the
Pik3ca
H1047R in immortalized cells may result from a cooperation
between Pik3ca
H1047R and the dominant-negative p53 used for
immortalization and provides further support for our contention
that Pik3ca
H1047R alone is insufficient to cause cancer and that
other secondary mutational events are required for tumorigenesis.
The tumors formed in response to Pik3ca
H1047R expression were
heterogenous in histology forming mainly benign fibroadenomas,
sarcomas and carcinosarcomas,. This range in tumor types is
Figure 6. Pik3ca
H1047R tumors express basal-like and luminal-like markers. (A) Mammary tumors from Pik3ca mutant mice were stained with
H&E or immunohistochemically stained with anti-K8/18, anti-K5/6, anti-ERa or anti-pAKT(Ser473). Shown are representative examples of a benign
fibroadenoma (i), carcinosarcoma (ii), and the squamous elements of an adenosquamous carcinoma (iii). Scale bar is 100 mm. (B) Mammary tumors
from Pik3ca mutant mice were stained for immunofluorescence using anti-K8 (red), anti-K5 (green), or anti-E-cadherin (pink). Dapi (blue) was used to
stain nuclei. Shown are representative examples of fibroadenoma (i), carcinosarcoma (ii), and the squamous elements of an adenosquamous
carcinoma (iii). The presence of a few K5 and K8 double-positive cells can be seen in the carcinosarcoma (arrows, middle panel). Scale bar is 50 mm.
doi:10.1371/journal.pone.0036924.g006
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H1047R
models [22,23,24] and is consistent with the heterogeneity
observed in human breast cancer. Since the MMTV-Cre targets
a multiple cell types within the mammary gland including both
ductal and luminal progenitors [29,30] the observed tumor
heterogeneity possibly reflects different cells of origin. Fibroade-
nomas and carcinosarcomas expressed both K5 and K8, markers
of ductal and luminal cells respectively, suggesting these tumor
types may derive from primitive multipotential progenitor cells.
The high proportion of ERa-positive tumors could indicate that
Pik3ca
H1047R tends to drive transformation down the luminal
pathway, a result consistent with our FACS data which showed an
expansion of the luminal progenitor population induced by
Pik3ca
H1047R in the developing mammary gland. On the other
hand, the adenosquamous carcinomas stained positively for K5
but did not express K8 or ERa suggesting they may be derived
from a differentiated myoepithelial cell. However, since the
expression of differentiation markers in tumor cells is not
Figure 7. Effects of Pik3ca
H1047R expression on in vitro proliferation and tumorigenicity of mammary epithelial cells. Isogenic
mammary epithelial cells expressing wild type or mutant Pik3ca were generated by isolating mammary epithelial cells from a Pik3ca
Lat-H1047R mouse
and immortalizing them with dominant-negative p53 and E1A. Expression of the mutant protein was induced using pMSCV-Cre-IRES-GFP and GFP
positive cells were isolated by FACS. Control cells expressing wild type Pik3ca were generated by infection with pMSCV-IRES-GFP retrovirus. (A) Wild
type (HB158
2) or mutant (HB158
+) mammary epithelial cells were seeded into 12-well plates at low density (20,000 cells) and cell growth monitored
over 68 hours using an IncuCyte
TM live cell imager to assess cell confluence. Shown are mean 6SD from a representative experiment performed in
triplicate. (B) Isogenic wild type (HB158
2) or mutant (HB158
+) cells were starved for 3 hours and then stimulated with 20% FBS for 15 minutes. Where
indicated, cells were treated with 20 mM of the PI3K inhibitor LY-294002 (LY) added at time of starvation. Protein lysates were separated by SDS-PAGE
and immunoblotted with anti-pAKT, anti-pGSK3b, anti-pS6, and anti-Tubulin (loading control). (C) Immortalized wild type (HB158
2) and mutant
(HB158
+) mammary epithelial cells (3610
6 cells) were injected into mammary fat pads of immunocompromised (SCID) recipient mice. Shown is the
Kaplan-Meier survival curve for injected mice (i) and representative sections from the undifferentiated carcinomas, formed by the Pik3ca
H1047R-
expressing cells (HB158
+), stained with H&E (ii), anti-pS6 (iii) or anti-ERa (iv). Scale bars, 100 mm.
doi:10.1371/journal.pone.0036924.g007
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no firm conclusions can be drawn as to the cells of origin in this
model.
We have described a novel mouse model that accurately
reproduces the scenario of a somatic mutation in a single PIK3CA
allele as occurs in human breast tumors. Our results confirm that
Pik3ca
H1047R mutation, when expressed at endogenous and
physiologically relevant levels, predisposes to mammary tumori-
genicity. Furthermore, we have demonstrated that this mouse can
be used to study the biological consequences of PIK3CA mutations
both in vivo and in vitro and, as such, this model will be a powerful
tool for investigating the role of PIK3CA mutations in tumourigen-
esis. In addition, this mouse will be a valuable model for the
preclinical evaluation of therapies targeting the PI3K pathway.
Supporting Information
Figure S1 Immunohistochemical staining of mammary
glands. Sections of formalin-fixed paraffin-embedded mammary
tissue from control (MMTV-Cre) and mutant (Pik3-
ca
H1047R:MMTV-Cre) mice were stained with anti-smooth muscle
actin, anti-p63, anti-K8/18, or anti-b-catenin, antibodies and
counter stained with hematoxylin. (A) Smooth muscle actin (SMA)
expression of the periductal stroma of 12 week old mice. Arrows
indicate periductal SMA staining. (B) p63 expression in the ducts
and terminal end buds of 6 week old mice. Arrows indicate
examples of p63 staining of non-basal cells. (C) K8/18 expression
in the ducts and terminal end buds of 6 week old mice. (D) b-
catenin expression in the ducts and terminal end buds of 6 week
old mice. All Scale bars are 100 mm. Insets (top left) show lower
magnification image of surrounding regions.
(TIF)
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